N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS, METHODS AND USES

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A.szlig.11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices...

Full description

Saved in:
Bibliographic Details
Main Authors VANDERMEEREN, MARC MARIA PIERRE PELAGIE, MERCKEN, MARC HUBERT
Format Patent
LanguageEnglish
French
Published 12.02.2013
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A.szlig.11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices. L'invention concerne des anticorps, y compris des parties spécifiées ou des variantes génétiques, qui sont spécifiques au moins pour le site N-terminal bêta-amyloïde 11 humain, à savoir les peptides A.szlig.11-x. Elle concerne en outre des procédés de fabrication et d'utilisation de ces anticorps, y compris des formulations thérapeutiques, des modes d'administration et des dispositifs.
Bibliography:Application Number: CA20032498058